President Donald Trump has consistently demonstrated a preference for maintaining control over escalation rather than allowing events to dictate American strategy.
Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
Russia’s exit on November 7, 2023, from the Treaty on Conventional Armed Forces in Europe (CFE), with the U.S. and NATO partners suspending their participating in the treaty highlights real concerns.